- Editor’s note: Finally, after plenty of monoclonal antibodies have been stored by the U. S. government, hospital systems on the verge of collapse due to COVID-19 overcrowding, are finally giving them a go and mainstream media is covering this story!
- These are the same monoclonal antibodies used in the multiple drug cocktail to save the life of President Trump and may keep many from having to go to the hospital.
MONOCLONAL ANTIBODIES NOW ENCOURAGED BY BIDEN ADMIN.
+ Vanderbilt University Medical Center: U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC [April 6, 2021]
+ The Rachel Maddow Show on MSNBC: Feds aim to save Covid-flooded hospitals with antibody therapy facility
+ The New York Times: As Virus Cases Surge, Biden Administration Encourages More Use of Antibody Treatments – A top White House adviser said monoclonal antibody treatments, sometimes underused, could still be crucial in helping people with Covid-19 avoid getting very sick.
+ Association of American Physicians and Surgeons: Peter McCullough, MD testifies to Texas Senate HHS Committee – Doctors need to treat their COVID-19 patients and if so, an 85% reduction of hospitalizations would ensue. [Ed. note: Dr. McCullough says doctors sending positive tested patients home to wait for symptoms is not TREATING them, which they took an oath to do! Monoclonal antibodies is one of the treatments administered along with an anti-inflammatory, Vit. C & D, and zinc.]
+ Wall Street Journal: Why Is the FDA Attacking a Safe, Effective Drug? Ivermectin is a promising Covid treatment and prophylaxis, but the agency is denigrating it.
+ University of Oxford (UK): Ivermectin to be investigated as a possible treatment for COVID-19 in Oxford’s PRINCIPLE trial
+ The Washington Post: Monoclonal antibodies are a freely available treatment for covid-19 that can prevent severe disease if given early enough to patients. Donald Trump, when he became sick as president, received them. But patients are rarely taking this therapy now. Fewer than 30 percent of eligible patients have taken Regeneron Pharmaceuticals’ monoclonal antibodies, the drug company said. “It is absolutely the standard of care for covid-19,” one infectious-disease pharmacist told The Post. “It is my hope that clinics know that.” Source